Roche launches cobas(R) 4800 System in Canada for testing CT, NG and HPV

New cobas(R) 4800 System designed to increase laboratory efficiency and medical value

 

Roche Diagnostics Canada (SIX: RO, ROG; OTCQX: RHHBY) announced today the launch of a new Health Canada approved clinical laboratory system designed to increase laboratory testing efficiency and to accommodate current and long-term molecular diagnostic needs. The cobas(R) 4800 System combines in vitro diagnostic tests for Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG) and human papillomavirus (HPV) testing with fully-automated sample preparation and real-time polymerase chain reaction (PCR) technology. Designed to greatly improve laboratory workflow and provide useful information that physicians can immediately act upon, the new cobas(R) 4800 System is now available in Canada.

"With the introduction of the cobas(R) 4800 System in Canada, clinical laboratories now have access to Roche technology that is designed to deliver new standards in laboratory testing efficiency and medically relevant diagnostic information with increased testing throughput," said Christopher Parker, President and General Manager of Roche Diagnostics in Canada.

Roche designed the cobas(R) 4800 System to meet the needs of a majority of clinical laboratories. The system combines state-of-the-art sample preparation with Roche's proprietary real-time PCR technology for the amplification and detection of genetic material (deoxyribonucleic acid or DNA) associated with HPV, CT or NG infections. The intuitive, easy-to-use software integrates sample preparation, amplification and detection, and results management.

The HPV test is designed to detect the 14 HPV high-risk genotypes widely accepted to cause cervical cancer. In addition to identifying these 14 HPV genotypes as a group, the cobas(R) 4800 HPV test enables simultaneous and individual identification of the two genotypes (HPV 16 and 18) that put women at highest risk for cervical cancer. Roche's CT and NG tests detect bacterial DNA associated with chlamydia and gonorrhea infections and are designed to minimize the potential effect that bacterial DNA sequence variations could have on the ability to detect an infection.

Roche launched the cobas(R) 4800 System in countries that accept the CE-Mark in December 2009. The cobas(R) 4800 System is not available in the U.S.

 

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Roche Sequencing and Life Science. (2019, June 19). Roche launches cobas(R) 4800 System in Canada for testing CT, NG and HPV. News-Medical. Retrieved on July 14, 2024 from https://www.news-medical.net/news/20100507/Roche-launches-cobas(R)-4800-System-in-Canada-for-testing-CT-NG-and-HPV.aspx.

  • MLA

    Roche Sequencing and Life Science. "Roche launches cobas(R) 4800 System in Canada for testing CT, NG and HPV". News-Medical. 14 July 2024. <https://www.news-medical.net/news/20100507/Roche-launches-cobas(R)-4800-System-in-Canada-for-testing-CT-NG-and-HPV.aspx>.

  • Chicago

    Roche Sequencing and Life Science. "Roche launches cobas(R) 4800 System in Canada for testing CT, NG and HPV". News-Medical. https://www.news-medical.net/news/20100507/Roche-launches-cobas(R)-4800-System-in-Canada-for-testing-CT-NG-and-HPV.aspx. (accessed July 14, 2024).

  • Harvard

    Roche Sequencing and Life Science. 2019. Roche launches cobas(R) 4800 System in Canada for testing CT, NG and HPV. News-Medical, viewed 14 July 2024, https://www.news-medical.net/news/20100507/Roche-launches-cobas(R)-4800-System-in-Canada-for-testing-CT-NG-and-HPV.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Roche Diagnostics launches first in vitro diagnostic ROS1 immunohistochemistry assay